BioSpace News Archive

Drug Development

Ampio Stock Craters After FDA Rejects Trial Changes

Ampio shares continue to fall following the company’s announcement that the FDA rejected proposed changes to a Phase III study of its treatment for osteoarthritis of the knee and other joints.

April 21, 2022
·
2 min read
·
Alex Keown
Drug Development

Research Roundup: COVID-19 Pneumonia and Dementia Risk, Prostate Cancer Advances - and Oreos

COVID-19 continues to generate surprises, such as a possible link between dementia and severe COVID-19. Continue reading for that and more research stories.

April 21, 2022
·
5 min read
·
Mark Terry
Drug Development

AstraZeneca Touts Evusheld’s Efficacy in High-Risk Patients

Clinical results announced this week could expand COVID-19 prevention options for the immunocompromised and vaccine ineligible, as well as those that have already contracted COVID.

April 21, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
Business

Expert Cancer Panel Calls for Permanent Shift to Global Clinical Trials

Thirty-five members of the Bloomberg New Economy International Cancer Coalition issued a call for a permanent change to the way cancer is diagnosed and treated around the world.

April 21, 2022
·
5 min read
·
Mark Terry
Business

Ultragenyx, Mereo Embark on Key Osteogenesis Imperfecta Trial

Ultragenyx and Mereo celebrated their first patient dosed in a Phase II/III study investigating the use of setrusumab as a treatment for osteogenesis imperfecta (OI).

April 21, 2022
·
2 min read
·
Jazmine Colatriano, M.S.
Business

The COVID-19 Pandemic will End, with Implications for Biopharma

The COVID-19 pandemic will end one day and, when it does, some biopharma companies will need to revert to a more normal way of working with others.

April 21, 2022
·
4 min read
·
Gail Dutton
Business

BioSpace Movers & Shakers: John Maraganore, Larry Alstiel, Brad Margus and More

Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.

April 21, 2022
·
7 min read
·
Alex Keown
Business

Sanofi Strikes Deal With Mysterious Psychedelics Biotech Terran

New York-based Terran Biosciences inked a deal with Paris-based Sanofi for two late-stage central nervous system (CNS) assets. Terran plans to advance them for neurological and psychological indications.

April 21, 2022
·
3 min read
·
Mark Terry
Drug Development

Novavax’s Mixed Day: Encouraging Combo Vaccine Data and EUA Update

The FDA noted that the EUA application for Novavax’s COVID-19 shot may take a while to be resolved, citing an “incredibly complex review process.”

April 21, 2022
·
2 min read
·
Vanessa Doctor, RN
Policy

UK Workers Union Offers GSK Small Window to Avoid Strike

British employees of pharma giant GlaxoSmithKline (GSK) have voted to strike against the company’s recent pay raise. The employees are backed by British labor union Unite.

April 21, 2022
·
2 min read
·
Hannah Chudleigh